Clinical Trials Logo

Clinical Trial Summary

Since the introduction of pneumococcal conjugate vaccines, this research group has conducted several carriage studies. These were at key points in the evolution of the pneumococcal immunisation schedule, with regard to the introduction of PCV7, the change to PCV13 and the impending change in number of doses of PCV13 given to infants. The last carriage study, conducted in 2015/16 identified interesting changes in carriage patterns which will further be explored by the current planned study.

Nasopharyngeal swabs and saliva swabs will be taken from healthy subjects and any pneumococci present will be cultured and serotyped using standard methods, as per our previous studies (Hussain et al., 2005; Flasche et al., 2011; van Hoek et al., 2014).


Clinical Trial Description

Streptococcus pneumoniae frequently colonises the human nasopharynx and most carriers remain asymptomatic. However, sometimes the organism may spread locally to cause non-invasive, mucosal infections such as sinusitis and otitis media or may invade the bloodstream and cause serious infections, including septicaemia, meningitis and pneumonia. In the 2005/06 epidemiological year, there were 6,391 cases of invasive pneumococcal diseases in England and Wales, with the highest incidence in the first year of life. The risk of developing invasive disease is dependent on both the susceptibility of the host and the invasiveness of the pneumococcus, which is largely determined by the characteristics of its polysaccharide capsule. Of the >90 known pneumococcal serotypes, the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) included in the 7-valent pneumococcal conjugate vaccine (PCV7) accounted for around 75% of childhood IPD cases in England and Wales prior to routine pneumococcal vaccination.

There have been several carriage studies conducted by this group at key points in the evolution of the pneumococcal vaccination policy of the UK, before use of any PCV, once the PCV7 had been introduced and once the change to PCV13 had been made. Studies have shown that conjugate vaccines, of which PCV7 and PCV13 are examples, can affect carriage of the bacteria against which the vaccinate. This series of carriage studies is important in understanding which pneumococcal strains are in the nose and so are potentially part of the chain of transmission as the vaccinations given have changed. For pneumococcus, where there are many strains, it is important to understand whether clearing carriage of a strain contained in the vaccine creates a niche which can be exploited by a strain of greater virulence or one which causes more serious disease. Our last such study suggested there are changes which we should continue to monitor, which is why the current study is now happening.

Nasopharyngeal swabs and saliva swabs will be taken from healthy subjects and any pneumococci present will be cultured and serotyped using standard methods, as per our previous studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03407690
Study type Observational
Source Public Health England
Contact
Status Completed
Phase
Start date February 14, 2018
Completion date July 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Completed NCT04042246 - Effect of Knowledge on Vaccine Take-up in Adamawa State, Northeastern Nigeria N/A
Enrolling by invitation NCT05570630 - VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination N/A
Completed NCT03145324 - Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations
Recruiting NCT06185647 - Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Recruiting NCT05215327 - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients Phase 2
Completed NCT03355989 - Evaluation of Conditional Cash Transfers (CCTs) for Immunization N/A
Completed NCT02992925 - Phase 3 Study of BK1310 in Healthy Infants Phase 3
Completed NCT03121638 - Safety Study of NBP608 in Healthy Adult Volunteers Phase 1
Not yet recruiting NCT05171946 - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults Phase 1
Completed NCT05661890 - Seasonal Influenza and Pneumococcal Vaccination in the Elderly
Active, not recruiting NCT04444518 - Increasing Influenza and Tdap Vaccination of Pregnant Women N/A
Active, not recruiting NCT03908164 - Optimising the Timing of Whooping Cough Immunisation in MUMs Phase 4
Completed NCT03379467 - Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage N/A
Not yet recruiting NCT03402646 - Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study N/A
Completed NCT04824638 - BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers Phase 2
Recruiting NCT05774093 - Evaluation of COVID-19 Immune Barrier and Reinfection Risk
Completed NCT03083158 - Immunity to Hepatitis B Vaccine Phase 4
Recruiting NCT04816760 - Immune Cells Phenotypes During COVID-19
Completed NCT04870021 - Hepatitis B Birth Dose for Newborns Phase 4